LAT is pleased to announce the initiation of a new Protocol in COVID_19. The purpose of this study is to assess the efficacy of RUTI® vaccine preventing SARS-CoV-2 infection (COVID-19) in healthcare workers.

The FDA approves Nifurtimox for the treatment of Chagas disease in children aged up to 18 years in the US. The most relevant study was run in Argentina, Bolivia and Colombia. LAT Research feels very proud of our contribution to this huge success working together with Bayer Team

LAT has started a new Clinical Trial to treat positive COVID-19 patients using hyperimmune serum developed with antibodies from horses. The clinical trial expects to enroll 242 patients diagnosed with the disease in moderate to severe conditions.

LAT is pleased to announce the initiation of a new Protocol in Hemolytic Uremic Syndrome. The Study will be the first approved treatment in the world to prevent the development of HUS, a serious disease that mainly affects boys under 10 years of age and can lead to dialysis, kidney transplantation or even death.

LAT staff has led a new GCP FDA inspection. Due to the pandemic, it was a remote inspection to review data of the site located in Argentina. The challenge was passed successfully.

LAT has great news to share! We are starting a new study in Mexico in patients with uncontrolled hypertension. This study is being run in collaboration with our partner AZIDUS BRASIL.